SAN DIEGO, Aug. 29, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), announced today that SCILEX Pharmaceuticals Inc. ("SCILEX"), a majority-owned subsidiary of Sorrento, resubmitted the NDA and responded to all of FDA...

Read more

- Marketing Authorization Application is expected to be filed in mid-2017 NEWS PROVIDED BY Sorrento Therapeutics, Inc. Jan 09, 2017, 09:00 ET SAN DIEGO, Jan. 9, 2017 /PRNewswire/ -- SCILEX Pharmaceuticals Inc. ("SCILEX"), a subsidiary of Sorrento Therapeutics,...

Read more

- 505(b)(2) NDA resubmission is expected in mid-2017 December 5, 2016 SAN DIEGO, Dec. 5, 2016 /PRNewswire/ -- SCILEX Pharmaceuticals Inc. ("SCILEX"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") today announced that its pivotal study...

Read more

November 8, 2016 SAN DIEGO, Nov. 8, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento") and Scilex Pharmaceuticals Inc. ("SCILEX") announced today the closing of a transaction by which Sorrento acquired a majority of SCILEX. ...

Read more

MALVERN, Pa.--(BUSINESS WIRE)--SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, reported data on how healthcare providers are currently treating patients with post-herpetic neuralgia...

Read more

Malvern, PA, February 23, 2016 – SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced the appointment of medical and regulatory affairs...

Read more

MALVERN, Pa., Dec. 10, 2015 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced the appointment of senior executives as...

Read more

Malvern, PA, September 16, 2015 – SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced that the FDA has accepted for filing...

Read more

Dr. Sanjay Gupta, President of the American Pain Association and a renowned physician with pain management expertise Dr. Philip Gerbino, an award-winning global pharmaceutical consultant and industry expert on market access MALVERN, Pa., June...

Read more

SCILEX PHARMACEUTICALS ANNOUNCES STRATEGIC INVESMENT BY ITOCHU CHEMICAL FRONTIER CORPORATION Malvern, PA – March 19, 2015 – SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today...

Read more